| 6-OHDA | 6-hydroxydopamine |
| ADAM17 | A disintegrin and metalloproteinase 17 |
| ADC | Antibody-drug conjugate |
| CD163 | Cluster of differentiation 163 |
| CSF-1R | Colony stimulating factor 1 receptor |
| CXCL | Chemokine ligand |
| EMA | European Medicines Agency |
| EMR1 | EGF-like module-containing mucin-like hormone receptor-like 1 |
| FDA | U.S. Food and Drug Administration |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor |
| HCC | Hepatocellular carcinoma |
| IFN-γ | Interferon-gamma |
| IL | Interleukin |
| iNOS | Nitric oxide synthase |
| IVIS | In vivo imaging system |
| LPS | Lipopolysaccharide |
| MARCO | Macrophage receptor with collagenous structure |
| M-CSF | Macrophage colony-stimulating factor |
| MRI | Magnetic resonance imaging |
| NASH | Non-alcoholic steatohepatitis |
| PBMC | Peripheral blood mononuclear cells |
| PD-1 | Programmed cell death protein 1 |
| PEG | Polyethylene glycol |
| PET | Positron emission tomography |
| PGE2 | Prostaglanding E2 |
| sCD163 | Soluble CD163 |
| STAT3 | Signal transducer and activator of transcription 3 |
| TAM | Tumor-associated macrophages |
| TGF-β | Transforming growth factor beta |
| TLR | Toll-like receptor |
| TNF-α | Tumor necrosis factor alpha |
| TWEAK | Tumor necrosis factor-like weak inducer of apoptosis |